Taking into account the high aggressivity of PCa, particularly mCRPC, and the success of PD−1/PD-L1 blockade in other cancers, patients with mCRPC could benefit from correct modulation of the immune system and, hence, from the use of checkpoint inhibitors [18]. Here, CD274 is linked to posterior cortical atrophy.